Medtronic (NYSE: MDT) and Arch Therapeutics (OTCMKTS:ARTH) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Medtronic pays an annual dividend of $1.84 per share and has a dividend yield of 2.2%. Arch Therapeutics does not pay a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Medtronic has raised its dividend for 39 consecutive years.
Medtronic has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Arch Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Insider and Institutional Ownership
81.9% of Medtronic shares are held by institutional investors. Comparatively, 0.0% of Arch Therapeutics shares are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Medtronic and Arch Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Medtronic and Arch Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medtronic||$29.71 billion||3.74||$4.03 billion||$3.64||22.53|
|Arch Therapeutics||N/A||N/A||-$7.78 million||($0.04)||-19.25|
Medtronic has higher revenue and earnings than Arch Therapeutics. Arch Therapeutics is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Medtronic and Arch Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medtronic presently has a consensus price target of $88.75, indicating a potential upside of 8.23%. Arch Therapeutics has a consensus price target of $2.83, indicating a potential upside of 267.97%. Given Arch Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Arch Therapeutics is more favorable than Medtronic.
Medtronic beats Arch Therapeutics on 11 of the 15 factors compared between the two stocks.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.